PT - JOURNAL ARTICLE AU - Lee, Todd C. AU - Murthy, Srinivas AU - Del Corpo, Olivier AU - Senécal, Julien AU - Butler-Laporte, Guillaume AU - Sohani, Zahra N AU - Brophy, James M. AU - McDonald, Emily G. TI - Remdesivir for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis AID - 10.1101/2022.01.22.22269545 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.22.22269545 4099 - http://medrxiv.org/content/early/2022/01/23/2022.01.22.22269545.short 4100 - http://medrxiv.org/content/early/2022/01/23/2022.01.22.22269545.full AB - Background The benefits of remdesivir in the treatment of hospitalized patients with Covid-19 remain debated with the National Institutes of Health and the World Health Organization providing contradictory recommendations for and against use.Methods We performed a systematic review of randomized controlled trials (RCTs) of remdesivir for the treatment of hospitalized patients with COVID-19. The primary outcome was mortality, stratified by oxygen use (none, supplemental oxygen without mechanical ventilation, and mechanical ventilation). We conducted a frequentist random effects meta-analysis on the risk ratio (RR) scale and, to better contextualize the probabilistic benefits, we also performed a bayesian random effects meta-analysis on the risk difference scale.Results We identified 8 randomized trials, totaling 9157 participants. The RR for mortality comparing remdesivir versus control was 0.71 (95% confidence interval [CI] 0.42-1.22; I2=0.0%) in the patients who did not require supplemental oxygen; 0.83 (95%CI 0.73-0.95; I2=0.0%) for nonventilated patients requiring oxygen; and 1.19 (95%CI 0.98-1.44 I2=0.0%) in the setting of mechanical ventilation. Using neutral priors, the probabilities that remdesivir reduces mortality were 74.7%, 96.9% and 8.9%, respectively. The probability that remdesivir reduced mortality by more than 1% was 88.1% for nonventilated patients requiring oxygen.Conclusion Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy.Competing Interest StatementDr. Murthy was the principal investigator and Dr. Lee was a co-investigator on CATCO, the Canadian arm of the WHO SOLIDARITY trial.Funding StatementDrs Lee, McDonald and Brophy receive research salary support from the Fonds de Recherche Quebec - Sante. Dr Butler-Laporte is supported by a scholarship from the Fonds de Recherche Quebec - Sante and the Ministere de la Sante et des Services sociaux. Dr. Murthy holds the Health Research Foundation of Innovative Medicines Canada Chair in Pandemic Preparedness Research. The CATCO trial was funded by the Canadian Institutes of Health Research (CIHR). The funders had no influence on the conduct or content of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.